These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37367185)

  • 1. Baseline Seroprevalence of SARS-CoV-2 Specific Antibodies in Hot Spot Areas of Great Tunis, up to 3 Months Post Disease Onset in Tunisia.
    Dhaouadi S; Letaief H; Hechaichi A; Safer M; Moussa R; Bouhali R; Letaief F; Abdelkader L; Ben Salah H; El Mili N; Hammami M; Talmoudi K; Souteyrand Y; Nabeth P; Kouni Chahed M; Bouafif Ép Ben Alaya N
    Epidemiologia (Basel); 2023 Jun; 4(2):188-201. PubMed ID: 37367185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis.
    Cherif I; Kharroubi G; Chaabane S; Yazidi R; Dellagi M; Snoussi MA; Salem S; Marzouki S; Kammoun Rebai W; Rourou S; Dellagi K; Barbouche MR; Benabdessalem C; Ben Ahmed M; Bettaieb J
    Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of SARS-CoV-2 infection among workers in a public health laboratory in Tunisia.
    Kharroubi G; Cherif I; Ghawar W; Dhaouadi N; Yazidi R; Chaabane S; Snoussi MA; Salem S; Ben Hammouda W; Ben Hammouda S; Gharbi A; Bel Haj Hmida N; Rourou S; Dellagi K; Barbouche MR; Benabdessalem C; Ben Ahmed M; Bettaieb J
    Arch Virol; 2023 Jan; 168(2):69. PubMed ID: 36658402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study.
    Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ
    Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of transmission chains and clusters associated with COVID-19 in Tunisia.
    Safer M; Letaief H; Hechaichi A; Harizi C; Dhaouadi S; Bouabid L; Darouiche S; Gharbi D; Elmili N; Ben Salah H; Hammami M; Talmoudi K; Moussa R; Charaa N; Termiz H; Ltaief F; Tounekti H; Makhlouf M; Belguith Sriha A; Ben Fredj M; Khalfallah S; Jabrane H; Mchirgui S; Amich C; Dabghi R; Anez Z; Abdelkader L; Mhamdi M; Ouerfeli N; Zoghlami S; Bougatef S; Chahed MK; Bouafif Ben Alaya N
    BMC Infect Dis; 2021 May; 21(1):453. PubMed ID: 34011266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Seroprevalence of SARS-CoV-2 in Mwanza, Northwestern Tanzania: A Population-Based Survey.
    Nyawale HA; Moremi N; Mohamed M; Njwalila J; Silago V; Krone M; Konje ET; Mirambo MM; Mshana SE
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of anti-SARS-CoV-2 antibodies and associated factors among household contacts of COVID-19 confirmed cases in Bangkok, Thailand.
    Atsawawaranunt K; Thiangthangthum K; Sirikhetkon S; Jampathong P; Kongklieng A; Nakphook S; Phonsingh P; Yorsaeng R; Praphasiri P; Mungaomklang A
    Heliyon; 2023 May; 9(5):e16501. PubMed ID: 37251836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and epidemiological features of COVID-19-related deaths in Tunisia before the emergence of VOCs (March 2020-February 2021)].
    Dhaouadi S; Hechaichi A; Letaief H; Safer M; Mziou E; Talmoudi K; Borgi C; Chebbi H; Somrani N; Ali MB; Yahyaoui S; Mseddi A; Chahed MK; Ferjani M; Alaya NB
    Pan Afr Med J; 2022; 43():172. PubMed ID: 36879635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys.
    Al-Abri SS; Al-Wahaibi A; Al-Kindi H; Kurup PJ; Al-Maqbali A; Al-Mayahi Z; Al-Tobi MH; Al-Katheri SH; Albusaidi S; Al-Sukaiti MH; Al Balushi AYM; Abdelgadir IO; Al-Shehi N; Morkos E; Al-Maani A; Al-Rawahi B; Alyaquobi F; Alqayoudhi A; Al-Harthy K; Al-Khalili S; Al-Rashdi A; Al-Shukri I; Al Ghafri TS; Al-Hashmi F; Al Jassasi SM; Alshaqsi N; Mitra N; Al Aamry HS; Shah P; Al Marbouai HH; Al Araimi AH; Kair IM; Al Manji AM; Almallak AS; Al Alawi FK; Vaidya V; Muqeetullah M; Alrashdi H; Al Jamoudi SSN; Alshaqsi A; Al Sharji A; Al Shukeiri H; Al-Abri B; Al-Rawahi S; Al-Lamki SH; Al-Manji A; Al-Jardani A
    Int J Infect Dis; 2021 Nov; 112():269-277. PubMed ID: 34601146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of seroprevalence in a cohort of university students of Rome (Italy) between September 2020 and July 2021.
    Ulivieri A; Morgante A; Magi F; Salehi LB; Lavra L
    Epidemiol Prev; 2022; 46(5-6):367-375. PubMed ID: 36628641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru.
    Reyes-Vega MF; Soto-Cabezas MG; Cárdenas F; Martel KS; Valle A; Valverde J; Vidal-Anzardo M; Falcón ME; Munayco CV;
    EClinicalMedicine; 2021 Apr; 34():100801. PubMed ID: 33817611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Household transmission of SARS-CoV-2 from unvaccinated asymptomatic and symptomatic household members with confirmed SARS-CoV-2 infection: an antibody-surveillance study.
    Bhatt M; Plint AC; Tang K; Malley R; Huy AP; McGahern C; Dawson J; Pelchat M; Dawson L; Varshney T; Arnold C; Galipeau Y; Austin M; Thampi N; Alnaji F; Langlois MA; Zemek RL
    CMAJ Open; 2022; 10(2):E357-E366. PubMed ID: 35414597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic.
    Anand S; Montez-Rath M; Han J; Cadden L; Hunsader P; Kerschmann R; Beyer P; Boyd SD; Garcia P; Dittrich M; Block GA; Parsonnet J; Chertow GM
    JAMA Netw Open; 2021 Jul; 4(7):e2116572. PubMed ID: 34251441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol.
    Pouquet M; Decarreaux D; Prévot-Monsacré P; Hervé C; Werner A; Grosgogeat B; Blanché H; Rabiega P; Laupie J; Kochert F; Abraham N; Sebaoun JM; de Lamballerie X; Charrel R; Souty C; Camara I; Pergeline J; Noël H; Guerrisi C; Werf SV; Carrat F; Hanslik T; Blanchon T; Falchi A
    Pathogens; 2021 Jul; 10(7):. PubMed ID: 34358061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.